QYQX
Lv1
30 积分
2022-07-19 加入
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
9天前
已完结
-
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
16天前
已完结
-
CAR T-cell therapies in China: rapid evolution and a bright future
1个月前
已完结
-
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
1个月前
已完结
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
2个月前
已完结
-
Immune signatures of checkpoint inhibitor-induced autoimmunity - a focus on neurotoxicity
5个月前
已完结
-
The therapeutic potential of natural killer cells in neuropathic pain
5个月前
已完结
-
Neuroinflammation: An astrocyte perspective
5个月前
已完结
-
Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review
7个月前
已完结
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
8个月前
已完结